After Outlook Therapeutics (OTLK) announced that it received a complete response letter from the FDA for Lytenava in wet age-related macular degeneration, Chardan called the CRL “a significant setback for the company. However, the CRL does not mean the end for Lytenava, which has already been approved and launched in Germany and the United Kingdom, the analyst added. The firm, which views U.S. approval as unlikely in the absence of additional studies, has a Neutral rating and $3 price target on Outlook shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
- Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
- Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
- Outlook Therapeutics Reports Q3 2025 Earnings and Milestones
- Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year